中国医药科学Issue(16)：7-9,62,4.
替比夫定阻断慢性乙肝母婴传播研究及其安全性分析
Clinical studies on telbivudine blocking effect of mother-to-infant transformation of pregnant women with chronic hepatitis B virus and its safety analysis
摘要
Abstract
Objective To evaluate the blocking effect of telbivudine on mother-to-infant transformation of pregnant women with chronic hepatitis B virus and its safety analysis after the telbivudine therapy. Methods Ninety-two cases of pregnant women with chronic hepatitis B virus were divided into two groups, forty-six of treatment group and forty-six of control group. Pregnant women in the treatment group were treated with telbivudine 600 mg/d since 28 weeks and lasting for half a year, while the pregnant women in the control group did not take any antiviral drugs, and then comparing the HBV-DNA negative transformation rate and ALT recovery rate of pregnant women before in hospital and giving birth. Babies were injected with HBIG and hepatitis B vaccine. The HBsAg were detected and the developments of the new babies were observed with the use of Apgar score.ResultsThe ALT and HBV-DNA levels were descended of pregnant women with chronic hepatitis B virus after treated with telbivudine, the values of the descending of the treatment group was significantly lower than the control group (P<0.05). In the treatment group, when new babies were born, 6, and 12 months old, the positive rates of HBV-DNA were 10.87%, 2.17%, 0; the positive rates of the control group were 28.26%, 21.74%, 13.0% (P<0.05). In the treatment group, when new babies were born, 6, and 12 months old, the positive rates of HBsAg were 8.7%、4.35%、2.17%; the positive rates of the control group were 32.61%、23.9%、15.22% (P<0.05). There were no significant differences in the Apgar scores of new babies of two groups.Conclusion Telbivudine is not only effective in treatment of pregnant women with chronic hepatitis B virus but also block mother-to-infant transformation, which was safer and will be widely applied in clinical.关键词
替比夫定/慢性乙型肝炎/母婴传播/安全Key words
Telbivudine/Chronic hepatitis B virus/Mother-to-infant transformation/Safe分类
医药卫生引用本文复制引用
任娜,胡善雷..替比夫定阻断慢性乙肝母婴传播研究及其安全性分析[J].中国医药科学,2015,(16):7-9,62,4.基金项目
国家十二五“艾滋病和病毒性肝炎等重大传染病防治”科技重大专项子课题（2012ZX10004301-005）。 （）
